<DOC>
	<DOCNO>NCT01806636</DOCNO>
	<brief_summary>This registry post market observational , prospective , multi-center registry . It design evaluate patient experience RePneu™ device relief emphysema symptom continue collection safety effectiveness data CE Mark product . In addition , registry collect information serve foundation cost effectiveness analysis .</brief_summary>
	<brief_title>Post Market Observational , Prospective , Multi-center Study</brief_title>
	<detailed_description />
	<mesh_term>Emphysema</mesh_term>
	<criteria>All adult patient diagnose homogeneous heterogeneous emphysema appropriate Coil treatment base CEMark Approved IFU schedule treatment RePneu procedure RV &gt; 175 % predict Post bronchodilator FEV1 ≤45 % predict . Normal international normalize ratio ( INR ) absence anticoagulation therapy Participant read , understood sign Informed Consent form Known uncontrolled pulmonary hypertension define systolic RVP &gt; 50mmHg Giant bullae &gt; 1/3 lung volume Patients antithrombotic treatment ( except aspirin ) stop 7 day prior treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Coil</keyword>
	<keyword>RePneu</keyword>
	<keyword>PneumRx</keyword>
	<keyword>LVRC</keyword>
</DOC>